Why Is Granules India Share Price Falling? Key Reasons & Share Price Target

Fri Apr 10 2026

Granules India is trading at Rs 418, down 38% from its 52-week high of Rs 680. The sustained fall in the Granules India share price has unsettled investors who built positions during the stock’s rally phase. At its current price, the stock is approaching its 52-week low of Rs 380, and the market is asking one question loudly: is this a buying opportunity, or is the decline a warning sign of deeper problems?

The Granules India share price falling is not random. There are specific, identifiable factors driving institutional selling, retail panic, and analyst downgrades — and this article examines each of them with real data from the latest quarterly results and exchange filings.

[Click Here – Get Free Investment Predictions](https://univest.in/user/log-in)

This article covers every key reason behind the Granules India share price fall, the latest financial performance data, technical levels to watch, institutional positioning, and what analysts think the Granules India share price target is for 2026.

Table of Contents

About Granules India

[Click Here – Get Free Investment Predictions on Univest.

Granules India is a listed company in the Pharmaceuticals / Generic API sector with a market capitalisation of Rs 10,500 Cr. The stock trades at approximately 16x trailing P/E and 2.4x price-to-book. Its 52-week range spans from Rs 380 to Rs 680, and the current price of Rs 418 puts the stock in the lower quarter of that range, reflecting the sustained selling pressure of recent months.

Why Is Granules India Share Price Falling? Key Reasons

Granules India Share Price Falling-Key Data 2026

[Tap to Access Best Research Pieces on Univest.

US Generic Drug Pricing Pressure — Paracetamol and Ibuprofen Market

Granules India is one of the world’s largest manufacturers of Paracetamol API and finished dosage forms. The US market for OTC analgesics, where Granules has significant private label exposure, has seen accelerated price erosion of 6-8% per year as large pharmacy chains consolidate procurement and negotiate harder with Indian generic manufacturers. The pricing environment shows no near-term signs of improvement.

FDA Warning Letter Risk — Historical Precedent

Granules India received an FDA warning letter for its Hyderabad Unit 1 facility in 2023, which was subsequently resolved. However, the pharmaceutical sector’s regulatory risk premium remains elevated for companies with prior FDA observations. Any fresh FDA inspection outcome that is less than fully satisfactory would trigger an immediate and sharp correction.

US Tariff Risk on Pharmaceutical Imports

While the Trump administration’s 26% tariff has a carve-out for certain pharmaceutical ingredients, there is ongoing uncertainty about how this will evolve. India supplies a significant portion of US generic drugs, and any tariff expansion to cover finished pharmaceutical products would be a direct negative for Granules.

Granules India Latest News That Impacted the Stock

October 2025: Q2 FY26: Revenue +9% YoY but PAT margin compresses to 14.5%.

January 2026: Q3 FY26: PAT down 4.2% YoY on pricing pressure.

February 2026: US FDA inspection of Hyderabad Unit 4 — VAI classification (acceptable outcome).

March 2026: Pharma sector de-rates on US tariff uncertainty; stock down 15%.

April 2026: Stock at Rs 418 — approaching 52-week low of Rs 380.

Granules India Financial Performance Analysis

The quarterly financial data for Granules India provides important context for understanding why the share price is falling. The numbers below highlight the key metrics that institutional analysts track closely.

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 1,140 Cr	Rs 1,055 Cr	+8.1% YoY
Net Profit (PAT)	Rs 158 Cr	Rs 165 Cr	-4.2% YoY
Market Cap	Rs 10,500 Cr	—	Current
P/E Ratio	16x	—	Trailing
P/B Ratio	2.4x	—	Current

If you want to track Granules India’s financial metrics in real time, check the Univest Screener for live data, peer comparisons, and financial history.

Technical Signals: What the Charts Are Saying

Granules India is trading at Rs 418, below all key moving averages including the 50-day, 100-day, and 200-day MAs. The stock has formed a clear pattern of lower highs and lower lows since its 52-week high of Rs 680. Key support is at the 52-week low of Rs 380. Resistance is at Rs 400 in the near term.

Download the Univest iOS App or Univest Android App to track Granules India’s live price and get daily research insights.

Market Sentiment and Institutional Positioning

Promoter holding stands at 38.6%, which is relatively modest and suggests limited promoter confidence buffer in volatile markets. FII holding at 18.4% is moderate, and DII holding at 24.6% indicates domestic institutions have meaningful exposure.

High FII ownership in any stock creates downside amplification when global risk appetite contracts. The Granules India share price falling has been exacerbated by FII selling that is driven by macro factors — crude oil, dollar strength, US rate expectations — rather than company-specific concerns alone.

Future Outlook: Can Granules India Recover?

Granules India at 16x P/E is one of the more reasonably valued mid-cap pharma companies. The 12-month target of Rs 520-600 implies 25-45% upside if US pricing pressure stabilises. The company is a genuine global leader in Paracetamol and Ibuprofen and has been expanding into more complex formulations and oncology APIs. Promoter holding of 38.6% is relatively low for comfort, but the founding family has consistently been involved operationally. Buy on sustained dips toward Rs 380-400 for long-term investors.

Granules India Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and F&O Setups.

Short-Term Target (3-6 Months)

In the short term, Granules India share price target is Rs 400-450 based on current technical positioning and near-term fundamental catalysts. The downside risk if the 52-week low of Rs 380 breaks is approximately 5-10% further.

12-Month Analyst Target

Analyst consensus 12-month Granules India share price target is Rs 520-600, implying significant upside from the current price of Rs 418. This target assumes a partial recovery of the factors driving the current decline.

Long-Term Target (FY27-FY28)

In a recovery scenario where the key headwinds resolve, the Granules India share price target for FY28 is Rs 700-850. This long-term bull case requires the fundamental concerns addressed in this article to show measurable improvement over the next 6-12 quarters.

For live Granules India tracking and peer comparison, explore the Univest Screener.

Conclusion

Granules India share price is falling due to a combination of company-specific headwinds and broader market pressures. The 52-week decline of 38% from the high of Rs 680 to the current Rs 418 has created both a risk and an opportunity. The risk is that the concerns identified in this article deepen; the opportunity is that the stock is now meaningfully cheaper than it was at the peak. Analyst consensus targets of Rs 520-600 for 12 months and Rs 700-850 for the longer term suggest significant potential upside for patient investors.

This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q1. Why is Granules India share price falling in 2026?

Granules India share price is falling due to the reasons detailed in this article, including sector-specific headwinds, recent financial performance concerns, and broader market pressures. The stock has fallen 38% from its 52-week high of Rs 680 to its current price of Rs 418. Investors should review all factors and consult a SEBI-registered financial advisor before making investment decisions.

Q2. What is Granules India share price target?

The 12-month analyst consensus Granules India share price target is Rs 520-600. The short-term target for 3-6 months is Rs 400-450, while the long-term target for FY27-FY28 is Rs 700-850 in a recovery scenario. These are analyst projections and not guaranteed returns.

Q3. Should I buy Granules India shares now?

This article cannot provide personalised investment advice. Granules India is trading at Rs 418 with a 52-week range of Rs 380 to Rs 680. Analyst consensus targets suggest potential upside. However, all the risks outlined in this article remain live. Consult a SEBI-registered financial advisor for personalised advice.

Q4. What is Granules India’s market cap and PE ratio?

Granules India’s current market capitalisation is Rs 10,500 Cr with a trailing P/E of 16x and price-to-book ratio of 2.4x. The stock is trading at Rs 418 as of April 2026.

Q5. What are Granules India’s latest quarterly results?

In the most recent quarter, Granules India reported revenue of Rs 1,140 Cr (+8.1% YoY) and net profit (PAT) of Rs 158 Cr (-4.2% YoY). Full quarterly financial data is available on the NSE/BSE filing portals and on the Univest Screener.

Q6. Who holds Granules India shares institutionally?

Granules India’s shareholding: Promoters 38.6%, FIIs 18.4%, DIIs 24.6%. Check the latest quarter’s shareholding pattern on NSE/BSE for the most current data.

Q7. What can trigger a recovery in Granules India share price?

Key recovery triggers for Granules India include: improvement in the fundamental factors causing the current decline, positive quarterly results showing reversal of the stressed metrics, broad market recovery, and any sector-specific positive news. Monitor developments closely.

Q8. What is the 52-week low of Granules India share price?

Granules India’s 52-week low is Rs 380, reached during the recent market correction. The 52-week high was Rs 680. The current price of Rs 418 represents a fall of 38% from the 52-week high. Technical analysts identify Rs 380 as a key support level.

For more analysis on falling stocks, visit Univest Blogs.